touchMDT Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations
Leading specialists and a patient advocate discuss novel immunotherapies for non-driver mutation metastatic non-small cell lung cancer (NSCLC).
Overview & Learning ObjectivesPatient with non-driver mutation metastatic NSCLC

Medical Oncologist, Oncology Pharmacist and Pathologist
Watch a medical oncologist, an oncology pharmacist and a pathologist discuss the limitations of standard-of-care immunotherapy for the treatment of non-driver mutation metastatic NSCLC.
Expert Spotlight
Prof. Raffaele Califano, Prof. Lisa Holle and Prof. Albrecht Stenzinger discuss the challenges associated with standard-of-care immunotherapy for metastatic NSCLC without driver mutations, including treatment resistance and toxicity.
Learn More Back to MDT Hub
Pathologist and Medical Oncologist
Watch a pathologist and a medical oncologist discuss prognostic and predictive biomarkers for immunotherapy.
Expert Spotlight
Prof. Albrecht Stenzinger and Prof. Raffaele Califano discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers.
Learn More Back to MDT Hub
Oncology Pharmacist and Medical Oncologist
Watch an oncology pharmacist and a medical oncologist review novel strategies to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC.
Expert Spotlight
Prof. Lisa Holle and Prof. Raffaele Califano review novel approaches to overcome resistance to standard-of-care immunotherapy for non-driver mutation metastatic NSCLC, including new immune checkpoint inhibitor combinations and emerging novel targets.
Learn More Back to MDT Hub
Medical Oncologist, Oncology Pharmacist and Patient Advocate
Watch a medical oncologist, an oncology pharmacist and a survivor of metastatic NSCLC discuss shared decision making and the importance of including patient preference in treatment decisions.
Expert Spotlight
Prof. Raffaele Califano and Prof. Lisa Holle are joined by Mr Josh Colow, a survivor of metastatic NSCLC. Together, they discuss the importance of involving patients in their treatment decisions and how clinicians can best support patients throughout their treatment journey.
Learn More Back to MDT Hub